Lana E Kandalaft

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3149850/publications.pdf

Version: 2024-02-01

69 papers	4,977 citations	126907 33 h-index	123424 61 g-index
71 all docs	71 docs citations	71 times ranked	7553 citing authors

#	Article	IF	Citations
1	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell, 2015, 28, 529-540.	16.8	601
2	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer Cell, 2019, 35, 885-900.e10.	16.8	475
3	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Science Translational Medicine, 2018, 10, .	12.4	326
4	Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. PLoS Computational Biology, 2017, 13, e1005725.	3.2	250
5	T cellâ€“induced CSF1 promotes melanoma resistance to PD1 blockade. Science Translational Medicine, 2018, 10, .	12.4	229
6	Whole Tumor Antigen Vaccines: Where Are We?. Vaccines, 2015, 3, 344-372.	4.4	203
7	A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clinical Cancer Research, 2013, 19, 4801-4815.	7.0	178
8	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discovery, 2022, 12, 108-133.	9.4	165
9	Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. OncoImmunology, 2013, 2, e22664.	4.6	154
10	Antitumour dendritic cell vaccination in a priming and boosting approach. Nature Reviews Drug Discovery, 2020, 19, 635-652.	46.4	148
11	Personalized Dendritic Cell Vaccinesâ€"Recent Breakthroughs and Encouraging Clinical Results. Frontiers in Immunology, 2019, 10, 766.	4.8	132
12	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. , 2019, 7, 109.		129
13	Sensitive and frequent identification of high avidity neo-epitopeÂspecific CD8 + T cells in immunotherapy-naive ovarian cancer. Nature Communications, 2018, 9, 1092.	12.8	122
14	Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells. , 2019, 7, 257.		120
15	Neutrophils suppress tumorâ€infiltrating T cells in colon cancer via matrix metalloproteinaseâ€mediated activation of <scp>TGF</scp> Î². EMBO Molecular Medicine, 2020, 12, e10681.	6.9	100
16	A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. Journal of Translational Medicine, 2012, 10, 157.	4.4	95
17	Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines. International Reviews of Immunology, 2011, 30, 150-182.	3.3	91
18	Rational combinations of immunotherapy with radiotherapy in ovarian cancer. Lancet Oncology, The, 2019, 20, e417-e433.	10.7	89

#	Article	IF	Citations
19	Angiogenesis and the Tumor Vasculature as Antitumor Immune Modulators: The Role of Vascular Endothelial Growth Factor and Endothelin. Current Topics in Microbiology and Immunology, 2010, 344, 129-148.	1.1	76
20	Immunotherapy in Ovarian Cancer: Are We There Yet?. Journal of Clinical Oncology, 2019, 37, 2460-2471.	1.6	73
21	A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinomaâ€"A Proof of Antigen Discovery Feasibility in Three Patients. Frontiers in Immunology, 2019, 10, 1832.	4.8	73
22	Myeloid antigen-presenting cell niches sustain antitumor TÂcells and license PD-1 blockade via CD28 costimulation. Cancer Cell, 2021, 39, 1623-1642.e20.	16.8	64
23	18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1859-1868.	6.4	62
24	Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Reports, 2021, 36, 109412.	6.4	60
25	A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. Journal of Translational Medicine, 2013, 11, 149.	4.4	57
26	Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors. Frontiers in Immunology, 2019, 10, 2283.	4.8	56
27	The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28â€"Costimulated T Cells Prepared for Adoptive Therapy. Clinical Cancer Research, 2015, 21, 2840-2850.	7.0	52
28	Tumor immune surveillance and ovarian cancer. Cancer and Metastasis Reviews, 2011, 30, 141-151.	5.9	47
29	Cancer Vaccines in Ovarian Cancer: How Can We Improve?. Biomedicines, 2016, 4, 10.	3.2	47
30	Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses. PLoS ONE, 2011, 6, e28732.	2.5	43
31	Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. Journal of Translational Medicine, 2011, 9, 198.	4.4	43
32	A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Journal of Translational Medicine, 2019, 17, 391.	4.4	42
33	Personalized approaches to active immunotherapy in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 72-82.	7.4	41
34	Sensitive identification of neoantigens and cognate TCRs in human solid tumors. Nature Biotechnology, 2022, 40, 656-660.	17.5	41
35	Immunotherapy for ovarian cancer. Current Opinion in Oncology, 2014, 26, 492-500.	2.4	36
36	Cryoablation and immunotherapy of cancer. Current Opinion in Biotechnology, 2020, 65, 60-64.	6.6	36

#	Article	IF	Citations
37	The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade. Gynecologic Oncology, 2010, 116, 222-233.	1.4	33
38	In vivo cancer vaccination: Which dendritic cells to target and how?. Cancer Treatment Reviews, 2018, 71, 88-101.	7.7	32
39	Potential approaches for more successful dendritic cell-based immunotherapy. Expert Opinion on Biological Therapy, 2015, 15, 569-582.	3.1	30
40	50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial. International Journal of Radiation Oncology Biology Physics, 2019, 103, 320-334.	0.8	28
41	Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting. Current Opinion in Biotechnology, 2020, 65, 233-241.	6.6	28
42	Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. Npj Vaccines, 2021, 6, 36.	6.0	27
43	Immune Therapy Opportunities in Ovarian Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e228-e240.	3.8	25
44	The current clinical landscape of personalized cancer vaccines. Cancer Treatment Reviews, 2022, 106, 102383.	7.7	25
45	A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNÎ± and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model. BioImpacts, 2018, 8, 211-221.	1.5	23
46	Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. Frontiers in Oncology, 2018, 8, 609.	2.8	17
47	The era of bioengineering: how will this affect the next generation of cancer immunotherapy?. Journal of Translational Medicine, 2017, 15, 142.	4.4	16
48	Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. , 2020, 8, e000875.		16
49	Deciphering the Mechanisms of Improved Immunogenicity of Hypochlorous Acid-Treated Antigens in Anti-Cancer Dendritic Cell-Based Vaccines. Vaccines, 2020, 8, 271.	4.4	13
50	Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine. Vaccines, 2020, 8, 25.	4.4	13
51	Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines. Current Opinion in Biotechnology, 2020, 65, 142-155.	6.6	12
52	Polymer Nanoparticleâ€Mediated Delivery of Oxidized Tumor Lysateâ€Based Cancer Vaccines. Macromolecular Bioscience, 2022, 22, e2100356.	4.1	10
53	Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment. Cytotherapy, 2020, 22, 780-791.	0.7	9
54	Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?. Current Opinion in Biotechnology, 2020, 65, 190-196.	6.6	9

#	Article	IF	Citations
55	Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery. Frontiers in Immunology, 2021, 12, 633910.	4.8	8
56	Rate of Freeze Impacts the Survival and Immune Responses Post Cryoablation of Melanoma. Frontiers in Immunology, 2021, 12, 695150.	4.8	8
57	Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?. Vaccines, 2018, 6, 79.	4.4	7
58	IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine. Cancers, 2019, 11, 40.	3.7	7
59	Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human. Cancers, 2021, 13, 4553.	3.7	6
60	Reduction-Sensitive Protein Nanogels Enhance Uptake of Model and Tumor Lysate Antigens In Vitro by Mouse- and Human-Derived Dendritic Cells. ACS Applied Bio Materials, 2021, 4, 8291-8300.	4.6	5
61	Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy. OncoImmunology, 2016, 5, e1062210.	4.6	4
62	Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. Cancers, 2021, 13, 5819.	3.7	4
63	Guillain-BarrÃ© syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes. , 2020, 8, e001155.		3
64	A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma. Cancers, 2021, 13, 5801.	3.7	2
65	Believe in yourself, and enjoy the ride. EBioMedicine, 2019, 49, 22.	6.1	0
66	Editorial overview: Pharmaceutical biotechnology: new frontiers in cancer immunotherapy. Current Opinion in Biotechnology, 2020, 65, iii-v.	6.6	0
67	Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform. Computational and Structural Biotechnology Journal, 2020, 18, 2217-2227.	4.1	0
68	In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study.. Journal of Clinical Oncology, 2021, 39, 2533-2533.	1.6	0
69	Tumor lysates cancer vaccine. , 2022, , 21-49.		0